Estimation of Cachexia among Cancer Patients Based on Four Definitions

Objectives. Estimate and compare the proportion of cancer patients with cachexia using different definitions from available clinical data. Methods. Electronic medical records were examined to estimate the proportion of cancer patients with cachexia using 4 definitions: (1) ICD-9 diagnostic code of 799.4 (cachexia), (2) ICD-9 diagnosis of cachexia, anorexia, abnormal weight loss, or feeding difficulties, (3) prescription for megestrol acetate, oxandrolone, somatropin, or dronabinol, and (4) ≥5% weight loss. Patients with cancer of the stomach, pancreas, lung, colon/rectum, head/neck, esophagus, prostate, breast, or liver diagnosed between 1999 and 2004 were followed for cachexia. Results. Of 8541 cancer patients (60% men and 55% Caucasian), cachexia was observed in 2.4% of patients using the cachexia diagnostic code, 5.5% expanded diagnoses, 6.4% prescription medication definition, and 14.7% with ≥5% weight loss. Conclusions. The proportion of patients with cachexia varied considerably depending upon the definition employed, indicating that a standard operational definition is needed.

[1]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[2]  G. Filippatos,et al.  Cachexia: common, deadly, with an urgent need for precise definition and new therapies. , 2008, The American journal of cardiology.

[3]  S. Anker,et al.  The need for a standardized definition for cachexia in chronic illness , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[4]  F. López‐Soriano,et al.  Muscle wasting in cancer and ageing: cachexia versus sarcopenia. , 2006, Advances in gerontology = Uspekhi gerontologii.

[5]  A. Jatoi,et al.  The cancer anorexia/weight loss syndrome: Therapeutic challenges , 2005, Current oncology reports.

[6]  S. Dudrick,et al.  What We Have Learned about Cachexia in Gastrointestinal Cancer , 2003, Digestive Diseases.

[7]  C. McArdle,et al.  A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. , 2003, Lung cancer.

[8]  B. Glimelius,et al.  The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. , 2002, Anticancer research.

[9]  E. Bruera,et al.  Update on anorexia and cachexia. , 2002, Hematology/oncology clinics of North America.

[10]  M. Maltoni,et al.  High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. McArdle,et al.  Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. , 1999, Nutrition and cancer.

[12]  A. Norman,et al.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? , 1998, European journal of cancer.

[13]  C. McArdle,et al.  Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. , 1998, Nutrition and cancer.

[14]  E. Bruera ABC of palliative care: Anorexia, cachexia, and nutrition , 1997 .

[15]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[16]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.